NCT04255589

A Clinical Trial to Evaluate the Efficacy and Safety of CKD-495

A Phase 3, Multi-center, Randomized, Double-blind, Parallel-group Trial to Evaluate the Efficacy and Safety of CKD-495 in Patients With Acute and Chronic Gastritis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 242 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

To Evaluate the Efficacy and Safety of CKD-495

Detailed description

A phase 3, Multi-center, Randomized, Double-blind, Parallel-group Trial to Evaluate the Efficacy and Safety of CKD-495 in Patients With Acute and Chronic Gastritis

Conditions

• Gastritis

Interventions

Type	Name	Description
DRUG	CKD-495 75mg	CKD-495 75mg Tab.
DRUG	Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg	Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
DRUG	Placebo of the CKD-495 75mg	Placebo of the CKD-495 75mg Tab.
DRUG	Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg	Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.

Timeline

• Start date: 2020-01-06
• Primary completion: 2021-05-20
• Completion: 2021-05-20
• First posted: 2020-02-05
• Last updated: 2021-07-02

Locations

17 sites across 1 country: South Korea